| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | RECRUITING | PHASE3 | 2025-06-30 | 2028-12-30 | 2027-12-31 |
| NCT06190899 | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | RECRUITING | PHASE1, PHASE2 | 2024-01-01 | 2027-11 | 2025-11 |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | RECRUITING | PHASE3 | 2022-12-08 | 2026-12-31 | 2025-06-30 |
| NCT02684032 | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | COMPLETED | PHASE1 | 2016-06-14 | 2022-01-19 | 2022-01-19 |